[go: up one dir, main page]

WO2007056539A3 - Prophylaxis and treatment of enterocolitis associated with anti-ctla-4 antibody therapy - Google Patents

Prophylaxis and treatment of enterocolitis associated with anti-ctla-4 antibody therapy Download PDF

Info

Publication number
WO2007056539A3
WO2007056539A3 PCT/US2006/043690 US2006043690W WO2007056539A3 WO 2007056539 A3 WO2007056539 A3 WO 2007056539A3 US 2006043690 W US2006043690 W US 2006043690W WO 2007056539 A3 WO2007056539 A3 WO 2007056539A3
Authority
WO
WIPO (PCT)
Prior art keywords
ctla
prophylaxis
treatment
antibody therapy
enterocolitis
Prior art date
Application number
PCT/US2006/043690
Other languages
French (fr)
Other versions
WO2007056539A2 (en
Inventor
Steven Fischkoff
Israel Lowy
James Chung-Yin Yang
Stephan R Targan
Original Assignee
Medarex Inc
Us Health
Steven Fischkoff
Israel Lowy
James Chung-Yin Yang
Stephan R Targan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medarex Inc, Us Health, Steven Fischkoff, Israel Lowy, James Chung-Yin Yang, Stephan R Targan filed Critical Medarex Inc
Publication of WO2007056539A2 publication Critical patent/WO2007056539A2/en
Publication of WO2007056539A3 publication Critical patent/WO2007056539A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention provides methods for reducing the incidence of adverse events related to immunotherapy. More specifically, the present invention provides methods for reducing the incidence of enterocolitis associated with anti- CTLA-4 antibody immunotherapy.
PCT/US2006/043690 2005-11-08 2006-11-08 Prophylaxis and treatment of enterocolitis associated with anti-ctla-4 antibody therapy WO2007056539A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73488105P 2005-11-08 2005-11-08
US60/734,881 2005-11-08

Publications (2)

Publication Number Publication Date
WO2007056539A2 WO2007056539A2 (en) 2007-05-18
WO2007056539A3 true WO2007056539A3 (en) 2008-11-20

Family

ID=38023996

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/043690 WO2007056539A2 (en) 2005-11-08 2006-11-08 Prophylaxis and treatment of enterocolitis associated with anti-ctla-4 antibody therapy

Country Status (2)

Country Link
US (1) US20070243184A1 (en)
WO (1) WO2007056539A2 (en)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8119129B2 (en) 2008-08-01 2012-02-21 Bristol-Myers Squibb Company Combination of anti-CTLA4 antibody with dasatinib for the treatment of proliferative diseases
EA023148B1 (en) 2008-08-25 2016-04-29 Эмплиммьюн, Инк. Compositions of pd-1 antagonists and use thereof
JP5740306B2 (en) * 2008-10-03 2015-06-24 ドクトル ファルク ファルマ ゲーエムベーハー Compositions and methods for treating bowel disease using mesalamine granules
WO2010042433A1 (en) 2008-10-06 2010-04-15 Bristol-Myers Squibb Company Combination of cd137 antibody and ctla-4 antibody for the treatment of proliferative diseases
AU2010308030B2 (en) * 2009-10-12 2014-05-29 Pfizer Inc. Cancer treatment
WO2013043569A1 (en) * 2011-09-20 2013-03-28 Vical Incorporated Synergistic anti-tumor efficacy using alloantigen combination immunotherapy
WO2013155487A1 (en) 2012-04-12 2013-10-17 Yale University Vehicles for controlled delivery of different pharmaceutical agents
TW201505635A (en) * 2013-05-21 2015-02-16 Salix Pharmaceuticals Inc Methods of treating ulcerative colitis
WO2015066535A1 (en) 2013-11-01 2015-05-07 Yale University Modular particles for immunotherapy
EP3498295A1 (en) 2014-05-28 2019-06-19 Agenus Inc. Anti-gitr antibodies and methods of use thereof
US20190194654A1 (en) 2014-10-24 2019-06-27 Astrazeneca Ab Combination
US20160347848A1 (en) 2015-05-28 2016-12-01 Medimmune Limited Therapeutic combinations and methods for treating neoplasia
WO2016196237A1 (en) 2015-05-29 2016-12-08 Agenus Inc. Anti-ctla-4 antibodies and methods of use thereof
CA3007233A1 (en) 2015-12-02 2017-06-08 Agenus Inc. Antibodies and methods of use thereof
US20170252417A1 (en) 2016-03-07 2017-09-07 Massachusetts Institute Of Technology Protein-chaperoned t-cell vaccines
EP3496746A4 (en) 2016-08-03 2020-02-12 Nextcure, Inc. Compositions and methods for modulating lair signal transduction
JP7069177B2 (en) 2016-09-21 2022-05-17 ネクストキュア インコーポレイテッド Antibodies to Siglec-15 and how to use them
EP4360714A3 (en) 2016-09-21 2024-07-24 Nextcure, Inc. Antibodies for siglec-15 and methods of use thereof
WO2018098352A2 (en) 2016-11-22 2018-05-31 Jun Oishi Targeting kras induced immune checkpoint expression
MA50949B1 (en) 2016-12-07 2023-12-29 Memorial Sloan Kettering Cancer Center ANTI-CTLA-4 ANTIBODIES AND METHODS OF USE THEREOF
CN118909118A (en) 2017-09-07 2024-11-08 奥古斯塔大学研究所公司 Programming cell death protein 1 antibodies
US20200368293A1 (en) * 2018-01-18 2020-11-26 Vedanta Biosciences, Inc. Compositions and methods for the treatment of cancer
WO2019147670A1 (en) 2018-01-23 2019-08-01 Nextcure, Inc. B7-h4 antibodies and methods of use thereof
WO2019169229A1 (en) 2018-03-01 2019-09-06 Nextcure, Inc. Klrg1 binding compositions and methods of use thereof
WO2020047345A1 (en) 2018-08-31 2020-03-05 Yale University Compositions and methods of using cell-penetrating antibodies in combination with immune checkpoint modulators
TW202028222A (en) 2018-11-14 2020-08-01 美商Ionis製藥公司 Modulators of foxp3 expression
JP7636330B2 (en) 2019-01-17 2025-02-26 ジョージア テック リサーチ コーポレイション Drug delivery system containing oxidized cholesterol - Patents.com
US11279932B2 (en) 2019-02-27 2022-03-22 Ionis Pharmaceuticals, Inc. Modulators of MALAT1 expression
US20220354880A1 (en) 2019-09-30 2022-11-10 Astrazeneca Ab Combination treatment for cancer
WO2021090146A1 (en) 2019-11-04 2021-05-14 Astrazeneca Ab Combination therapy for treating cancer
US11897950B2 (en) 2019-12-06 2024-02-13 Augusta University Research Institute, Inc. Osteopontin monoclonal antibodies
WO2021231350A1 (en) 2020-05-13 2021-11-18 Massachusetts Institute Of Technology Compositions of polymeric microdevices and their use in cancer immunotherapy
WO2022165403A1 (en) 2021-02-01 2022-08-04 Yale University Chemotherapeutic bioadhesive particles with immunostimulatory molecules for cancer treatment
CN118984837A (en) 2022-01-28 2024-11-19 乔治穆内公司 Antibodies to programmed cell death protein 1 as PD-1 agonists
WO2024050524A1 (en) 2022-09-01 2024-03-07 University Of Georgia Research Foundation, Inc. Compositions and methods for directing apolipoprotein l1 to induce mammalian cell death
WO2024081736A2 (en) 2022-10-11 2024-04-18 Yale University Compositions and methods of using cell-penetrating antibodies
WO2024112867A1 (en) 2022-11-23 2024-05-30 University Of Georgia Research Foundation, Inc. Compositions and methods of use thereof for increasing immune responses
WO2024150017A1 (en) 2023-01-13 2024-07-18 Akrivia Biomedics Limited Method of profiling diseases

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030103962A1 (en) * 2001-10-09 2003-06-05 Campbell Joy M. Methods and compositions for modulating the immune system of animals
US20040241169A1 (en) * 2003-05-30 2004-12-02 Medarex, Inc. Surrogate therapeutic endpoint for anti-CTLA4-based immunotherapy of disease
US20050107399A1 (en) * 2003-09-11 2005-05-19 Kemia, Inc. Cytokine inhibitors

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8903914D0 (en) * 1989-11-22 1989-11-22 Draco Ab ORAL COMPOSITION FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASES

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030103962A1 (en) * 2001-10-09 2003-06-05 Campbell Joy M. Methods and compositions for modulating the immune system of animals
US20040241169A1 (en) * 2003-05-30 2004-12-02 Medarex, Inc. Surrogate therapeutic endpoint for anti-CTLA4-based immunotherapy of disease
US20050107399A1 (en) * 2003-09-11 2005-05-19 Kemia, Inc. Cytokine inhibitors

Also Published As

Publication number Publication date
WO2007056539A2 (en) 2007-05-18
US20070243184A1 (en) 2007-10-18

Similar Documents

Publication Publication Date Title
WO2007056539A3 (en) Prophylaxis and treatment of enterocolitis associated with anti-ctla-4 antibody therapy
WO2007056540A3 (en) Tnf-alpha blocker treatment for enterocolitis associated with immunostimulatory therapeutic antibody therapy
WO2009112245A9 (en) Antibody against the csf-1 r
IL244803A0 (en) Humanized anti-beta7 antibodies and uses therefore
WO2012149356A3 (en) Anti-cd40 antibodies and methods of use
PH12017501417A1 (en) Anti-fap antibodies and methods of use
WO2008140493A3 (en) Anti-egfr family antibodies, bispecific anti-egfr family antibodies and methods of use thereof
EA200702180A1 (en) METHODS FOR THE TREATMENT OF IMMUNE DISORDERS RELATED TO TRANSPLANT TRANSPLANT WITH SOLUBLE MUTANT CTLA4
WO2006116423A3 (en) Compositions and methods for cancer immunotherapy
UA92505C2 (en) Anti-cd3 antibody formulations
WO2006003388A3 (en) Compositions and methods for treating inflammatory disorders
WO2010017103A3 (en) Fully human anti-human nkg2d monoclonal antibodies
WO2008103947A3 (en) Activation of human antigen-presenting cells through clec-6
MX2010006823A (en) Methods for the treatment of gout.
MX2009004532A (en) Compositions and methods for binding sphingosine-1-phosphate.
UA101487C2 (en) Humanized b-ly1 antibody formulation
WO2006096489A3 (en) Anti-m-csf antibody compositions having reduced levels of endotoxin
MX347020B (en) Antibody against the csf-1r.
WO2010032059A3 (en) Antibodies directed to cd105 and uses thereof
CA3019531A1 (en) Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer
TN2010000092A1 (en) Humanized cxcr5 antidodies, derivatives thereof and their uses
WO2008060705A8 (en) Anti-dll4 antibodies and methods using same
WO2009135861A3 (en) Humanized antibodies against human interferon-alpha
WO2005120557A3 (en) Inhibition of macrophage-stimulating protein receptor (ron)
WO2008112192A3 (en) Epha3 antibodies for the treatment of solid tumors

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06837269

Country of ref document: EP

Kind code of ref document: A2